

INTRODUCTION	XIII
STUDY GOAL AND OBJECTIVES	XIII
REASONS FOR DOING THIS STUDY	XIII
CONTRIBUTION OF THE STUDY AND FOR WHOM	XIV
SCOPE AND FORMAT	XIV
METHODOLOGY	XIV
ANALYST CREDENTIALS	XIV
RELATED BCC REPORTS	XV
BCC ONLINE SERVICES	XVI
DISCLAIMER	XVI
SUMMARY.....	XVII
SUMMARY TABLE U.S. CLINICAL TRIAL MARKET, THROUGH 2007.....	XVIII
SUMMARY FIGURE U.S. CLINICAL TRIAL MARKET, 2001, 2002, AND 2007.....	XIX
CLINICAL TRIAL OVERVIEW	1
TYPES OF CLINICAL TRIALS	1
CLINICAL TRIAL PHASES.....	1
FIGURE 1 NEW DRUG DEVELOPMENT TIMELINE.....	2
TABLE 1 CLINICAL TRIAL PHASES.....	3
PHASE I	3
PHASE II.....	4
PHASE III.....	4
PHASE IV/POSTMARKETING TRIALS	4
FACTORS AFFECTING STUDY SIZE.....	5
PHYSICIAN AND PATIENT RECRUITMENT	5
PHYSICIAN AND PATIENT RECRUITMENT (CONTINUED).....	6
GOVERNMENT REGULATIONS	7
TABLE 2 LAWS AFFECTING DRUG APPROVAL TIMES	7
FOOD AND DRUG ADMINISTRATION (FDA)	8
BACKGROUND	8
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER).....	8
TABLE 3 NEW BIOLOGICS APPLICATIONS AND AVERAGE APPROVAL TIME, THROUGH 2007.....	9
CBER and Bioterrorism	10
CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)	10
CDER and Bioterrorism	10
CENTER FOR DEVICES AND RADIOLOGIC HEALTH (CDRH)	10
TABLE 4 NEW DEVICE APPLICATIONS AND AVERAGE APPROVAL TIMES BY YEAR	11
EXPEDITED REVIEW	12
FIGURE 2 THE EXPEDITED REVIEW PROCESS	12

TABLE 5 NEW DRUG APPLICATIONS (NDAs) AND AVERAGE APPROVAL TIMES, THROUGH 2007.....	13
EXPEDITED DEVELOPMENT AND REVIEW.....	13
TABLE 6 DISEASE CATEGORIES DESIGNATED FOR PRIORITY REVIEW.....	14
Subpart E.....	14
Accelerated Approval (Subpart H).....	14
Priority Review.....	14
Fast Track.....	15
TABLE 7 NEW DRUG APPLICATION APPROVAL RATES, 1998, 2000, AND 2001.....	15
PEDIATRICS.....	15
INVESTIGATIONAL REVIEW BOARD (IRB).....	16
INTERNATIONAL CONFERENCE ON HARMONISATION (ICH).....	17
INDUSTRY/CLINICAL TRIAL MARKET.....	18
WHO FUNDS CLINICAL TRIALS?.....	18
TABLE 8 U.S. CLINICAL TRIAL FUNDING BY SOURCE, THROUGH 2007 (\$ MILLIONS).....	18
FIGURE 3 MAJOR FUNDING SOURCES FOR CLINICAL TRIALS, 2001, 2002, AND 2007 (\$ MILLIONS).....	19
TABLE 9 U.S. CLINICAL TRIALS FUNDED BY SOURCE, THROUGH 2007* (NUMBER OF CLINICAL TRIALS RECRUITING SUBJECTS).....	20
FIGURE 4 NUMBERS OF U.S. CLINICAL TRIALS BY MAJOR SPONSORS, 2002 (# OF TRIALS).....	20
BIOTECH/PHARMACEUTICAL COMPANIES.....	20
NATIONAL INSTITUTES OF HEALTH AND OTHER AGENCIES OF THE FEDERAL GOVERNMENT.....	21
PRIVATE ORGANIZATIONS, UNIVERSITIES AND SPECIALTY GROUPS.....	21
WHO CONDUCTS CLINICAL TRIALS?.....	22
TABLE 10 DIRECT SPENDING ON U.S. CLINICAL TRIALS BY ORGANIZATION TYPE, THROUGH 2007 (\$ MILLIONS).....	23
FIGURE 5 DIRECT SPENDING ON U.S. CLINICAL TRIALS BY ORGANIZATION, 2002 AND 2007.....	23
FIGURE 5 (CONTINUED).....	24
TABLE 11 U.S. CLINICAL TRIALS BY ORGANIZATION TYPE, THROUGH 2007 (NUMBER OF CLINICAL TRIALS RECRUITING SUBJECTS).....	24
CLINICAL TRIALS BY PHASE.....	25
TABLE 12 TOTAL U.S. SPENDING FOR CLINICAL TRIALS BY PHASE, THROUGH 2007 (\$ MILLIONS).....	25
FIGURE 6 TOTAL U.S. SPENDING FOR CLINICAL TRIALS BY PHASE, 2001, 2002, AND 2007 (\$ MILLIONS).....	26
TABLE 13 U.S. CLINICAL TRIALS BY PHASE, THROUGH 2007 (# OF TRIALS).....	26
FIGURE 7 NUMBERS OF CLINICAL TRIALS BY PHASE, 2001, 2002, AND 2007 (# OF TRIALS).....	27
FIGURE 8 U.S. CLINICAL TRIALS BY PHASE, 2002 AND 2007.....	27
Biopharmaceutical Industry.....	28
TABLE 14 AMOUNT SPENT BY PHASE ON U.S. CLINICAL TRIALS IN THE BIOPHARMACEUTICAL SECTOR, THROUGH 2007 (\$ MILLIONS).....	28
FIGURE 9 RATIO OF PHASES I – III TO PHASE IV, 2001, 2002, AND 2007 (\$ MILLIONS).....	28

TABLE 15 CLINICAL TRIALS BY PHASE IN THE BIOPHARMACEUTICAL SECTOR, THROUGH 2007 (NUMBERS OF CLINICAL TRIALS).....	29
FIGURE 10 CLINICAL TRIALS BY PHASE IN THE BIOPHARMACEUTICAL SECTOR, 2001, 2002, AND 2007 (# OF TRIALS).....	30
Academic Medical Centers/Specialty Clinics.....	30
TABLE 16 CLINICAL TRIAL FUNDING RECEIVED BY U.S. ACADEMIC MEDICAL CENTERS/SPECIALTY CLINICS BY SOURCE, THROUGH 2007 (\$ MILLIONS).....	30
FIGURE 11 CLINICAL TRIAL FUNDING RECEIVED BY U.S. ACADEMIC MEDICAL CENTERS/SPECIALTY CLINICS BY SOURCE, 2001, 2002, AND 2007 (\$ MILLIONS).....	31
Academic Medical Centers/Specialty Clinics (Continued)	32
TABLE 17 CLINICAL TRIALS AT ACADEMIC MEDICAL CENTERS/SPECIALTY CLINICS, BY PHASE, THROUGH 2007 (NUMBER OF CLINICAL TRIALS).....	33
Contract Research Organizations (CROs)	33
BIOTECHNOLOGY VS. PHARMACEUTICAL	34
TABLE 18 RESEARCH AND DEVELOPMENT FUNDING FOR MAJOR BIOPHARMACEUTICAL COMPANIES, BY DISEASE SYSTEM, THROUGH 2007 (\$ MILLIONS).....	35
FIGURE 12 RESEARCH AND DEVELOPMENT FUNDING FOR MAJOR BIOPHARMACEUTICAL COMPANIES, BY DISEASE SYSTEM, 2002 AND 2007.....	36
TABLE 19 NUMBER OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY-SPONSORED TRIALS, BY PHASE, ACCORDING TO DISEASE OR DISEASE SYSTEM IN 2001 (# OF TRIALS)	37
TABLE 20 TOP 10 BEST-SELLING DRUG CLASSES IN 2001 WITH PERCENT CHANGE FROM 2000 AND MARKET PERCENT.....	38
CLINICAL TRIAL RESEARCH AREAS	38
CLINICAL TRIAL RESEARCH AREAS (CONTINUED)	39
TABLE 21 NUMBER OF TRIALS BY MAJOR CLINICAL RESEARCH AREAS, THROUGH 2007.....	40
TECHNOLOGIES	41
TABLE 22 NUMBER OF CLINICAL TRIALS USING NEW TECHNOLOGIES, THROUGH 2007.....	41
TABLE 23 NEW TECHNOLOGIES AND PROJECTED EFFECTS ON CLINICAL TRIALS.....	42
TABLE 23 (CONTINUED)	43
ANTISENSE.....	43
APOPTOSIS	44
BIOCHIPS/MICROARRAYS	44
BIOINFORMATICS	44
BIOPROCESSORS.....	45
CELL AND CELL SIGNALING	46
CELL THERAPY.....	47
ELECTRONIC DATA CAPTURE (EDC) AND E-SUBMISSION	47
GENE THERAPY	48
GENOMICS.....	49
NOVEL DRUG DELIVERY SYSTEMS	49
PICAS®.....	50
THERANOSTICS	50

Natural Sources	50
<i>FIGURE 13 FACTORS INFLUENCING DRUG DEVELOPMENT</i>	51
FACTORS INFLUENCING DRUG DEVELOPMENT	52
EPIDEMIOLOGICAL TRENDS	52
LEGISLATION.....	53
NEW TECHNOLOGIES	53
BIOTERRORISM	54
CLINICAL TRIAL COSTS	55
FACTORS INFLUENCING CLINICAL TRIAL COSTS.....	55
FACTORS INCREASING CLINICAL TRIAL COSTS.....	55
FACTORS INCREASING CLINICAL TRIAL COSTS (CONTINUED).....	56
FACTORS DECREASING CLINICAL TRIAL COSTS	57
RECENT AND FUTURE TRENDS	57
RESEARCH AND DEVELOPMENT BUDGETS.....	58
BIOTECHNOLOGY COMPANIES	58
<i>TABLE 24 R&D EXPENDITURES, CLINICAL TRIAL COSTS AND PERCENTAGE OF R&D TO TOTAL REVENUES FOR TOP 10 BIOTECHNOLOGY COMPANIES, 2001 (\$ MILLIONS)</i>	58
Biotechnology Companies (Continued).....	59
<i>TABLE 25 PROJECTED R&D AND CLINICAL TRIAL COSTS FOR SELECTED U.S.- BASED BIOTECHNOLOGY COMPANIES, THROUGH 2007 (\$ MILLIONS)</i>	60
PHARMACEUTICAL COMPANIES	61
<i>TABLE 26 R&D EXPENDITURES, CLINICAL TRIAL COSTS AND PERCENTAGE OF R&D TO TOTAL REVENUES FOR TOP 10 PHARMACEUTICAL COMPANIES, 2001 (\$ MILLIONS)</i>	61
<i>TABLE 27 PROJECTED R&D AND CLINICAL TRIAL COSTS FOR SELECTED U.S.- BASED PHARMACEUTICAL COMPANIES, THROUGH 2007 (\$ MILLIONS)</i>	62
OUTSOURCING AND CONTRACT RESOURCE ORGANIZATIONS.....	62
GLOBALIZATION	63
Time-to-Market Pressures	64
Technology Changes will Increase Demand for CRO Services	64
Negative Pressures on the CRO Industry	65
PRODUCT PIPELINE.....	66
MAJOR COMPANY PRODUCT PIPELINES	66
BIOTECHNOLOGY PRODUCT PIPELINES	66
BIOLOGICS	67
<i>TABLE 28 BIOLOGICS UNDER CLINICAL TRIAL BY MANUFACTURER PIPELINE IN 2002</i>	67
DRUGS BY DISEASE.....	68
CARDIOVASCULAR	68
<i>TABLE 29 PRODUCTS FOR TREATING CARDIOVASCULAR DISEASE UNDER CLINICAL TRIAL, BY MANUFACTURER</i>	68
CENTRAL NERVOUS SYSTEM.....	69

<i>TABLE 30 PRODUCTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES IN PHASE III AND IV CLINICAL TRIALS, BY MANUFACTURER</i>	69
<i>TABLE 30 (CONTINUED)</i>	70
GASTROINTESTINAL DISEASE.....	70
<i>TABLE 31 PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISEASE IN PHASE III AND IV CLINICAL TRIALS, BY MANUFACTURER</i>	70
INFECTION	71
<i>TABLE 32 PRODUCTS FOR TREATMENT OF INFECTIOUS DISEASES IN PHASE III AND IV CLINICAL TRIALS</i>	71
INFLAMMATION	72
<i>TABLE 33 PRODUCTS IN PHASE III AND IV CLINICAL TRIALS FOR THE TREATMENT OF ANTI-INFLAMMATORY DISEASES</i>	72
CANCER.....	73
<i>TABLE 34 PRODUCTS FOR CANCER TREATMENT IN PHASE III AND IV CLINICAL TRIALS, BY MANUFACTURER</i>	73
ORTHOPEDICS	74
<i>TABLE 35 PRODUCTS FOR TREATMENT OF MUSCULOSKELETAL DISORDERS IN PHASE III AND IV CLINICAL TRIALS</i>	74
RESPIRATORY	75
<i>TABLE 36 PRODUCTS FOR TREATMENT OF RESPIRATORY DISEASES IN PHASE III AND IV CLINICAL TRIALS</i>	75
DRUGS BY COMPANY	76
BIOTECHNOLOGY COMPANIES	76
Amgen	76
<i>TABLE 37 AMGEN PRODUCT PIPELINE</i>	76
Genentech	77
<i>TABLE 38 GENENTECH PRODUCT PIPELINE</i>	77
Chiron	78
<i>TABLE 39 CHIRON PRODUCT PIPELINE</i>	78
Biogen.....	79
<i>TABLE 40 BIOGEN PRODUCT PIPELINE</i>	79
Genzyme.....	79
<i>TABLE 41 GENZYME PRODUCT PIPELINE</i>	79
<i>TABLE 41 (CONTINUED)</i>	80
Immunex	80
<i>TABLE 42 IMMUNEX PRODUCT PIPELINE</i>	80
MedImmune.....	81
<i>TABLE 43 MEDIMMUNE PRODUCT PIPELINE</i>	81
IDEC Pharmaceuticals.....	82
<i>TABLE 44 IDEC PHARMACEUTICALS PRODUCT PIPELINE</i>	82
Cephalon	82
<i>TABLE 45 CEPHALON PRODUCT PIPELINE</i>	82
Millennium Pharmaceuticals.....	83
<i>TABLE 46 MILLENNIUM PRODUCT PIPELINE</i>	83
Vertex.....	84
<i>TABLE 47 VERTEX PRODUCT PIPELINE</i>	84
PHARMACEUTICAL COMPANIES	84
Pfizer	84
<i>TABLE 48 PFIZER PRODUCT PIPELINE</i>	84

Pfizer (Continued).....	85
Merck	86
TABLE 49 MERCK PRODUCT PIPELINE	86
Johnson & Johnson.....	87
TABLE 50 JOHNSON & JOHNSON PRODUCT PIPELINE.....	87
Bristol-Myers Squibb.....	88
TABLE 51 BRISTOL-MYERS SQUIBB PRODUCT PIPELINE.....	88
Pharmacia	89
TABLE 52 PHARMACIA PRODUCT PIPELINE	89
Eli Lilly	90
TABLE 53 ELI LILLY PRODUCT PIPELINE.....	90
Wyeth	90
TABLE 54 WYETH PRODUCT PIPELINE	90
Schering-Plough.....	91
TABLE 55 SCHERING-PLOUGH PRODUCT PIPELINE.....	91
Abbott Laboratories.....	92
TABLE 56 ABBOTT PRODUCT PIPELINE.....	92
DEVICES.....	92
TABLE 57 RECENT MAJOR DEVICE APPROVALS	93
MARKET RESPONSE TO PRODUCT RELEASE.....	94
TABLE 58 MAJOR DRUG APPROVALS AND EFFECTS ON COMPANY STOCK PRICE.....	94
COMPANY PROFILES	95
BIOTECHNOLOGY COMPANIES	95
ACAMBIS	95
AMGEN	96
BIOGEN.....	97
CEPHALON	98
CHIRON	99
GENENTECH	99
GENENCOR INTERNATIONAL, INC.	100
GENZYME.....	100
HUMAN GENOME SCIENCES, INC.....	101
IDEC PHARMACEUTICALS	102
IMMUNEX.....	103
MILLENNIUM PHARMACEUTICALS, INC.....	104
SERONO.....	104
VERTEX	105
PHARMACEUTICAL COMPANIES.....	106
ABBOTT LABORATORIES	106
ASTRAZENECA.....	107
Astrazeneca (Continued).....	108
BAXTER INTERNATIONAL, INC.....	109
BRISTOL-MYERS SQUIBB	110
ELI LILLY	111

GLAXOSMITHKLINE	112
JOHNSON & JOHNSON.....	112
MERCK.....	113
NOVARTIS	113
PFIZER	114
PHARMACIA.....	114
SCHERING-PLOUGH	115
CONTRACT RESEARCH ORGANIZATIONS (CROs)	116
AAI	116
<i>FIGURE 14 AAI-223 SOLID ORAL DRUG DELIVERY SYSTEM</i>	<i>117</i>
ABT ASSOCIATES, INC.....	117
ALBANY MOLECULAR RESEARCH, INC.	118
ASTER CEPHAC.....	118
CAMBREX BIO SCIENCE, INC	118
BRI INTERNATIONAL, LTD.....	119
CATO RESEARCH, LTD.	119
CERB	119
CHILTERN INTERNATIONAL.....	120
CLINICAL TRIAL SERVICES	120
CLINICAL TRIALS SUPPORT SERVICES, INC.	120
CLINTRIALS RESEARCH, INC.	120
COVANCE, INC.	121
<i>FIGURE 15 COVANCE 2001 DISTRIBUTION OF NET REVENUES.....</i>	<i>121</i>
INGENIX PHARMACEUTICAL SERVICES	121
HEALTH DECISIONS, INC.....	122
KENDLE INTERNATIONAL, INC.....	122
OMNICARE CLINICAL RESEARCH	122
PAREXEL INTERNATIONAL CORP.....	123
PPD, INC.	123
QUINTILES TRANSNATIONAL.....	124
RESEARCH TRIANGLE INSTITUTE.....	124
SEQUITUR, INC.....	124
SIMBEC RESEARCH, LTD.....	125
THE PHARMACEUTICAL EDUCATION & RESEARCH INSTITUTE, INC.....	125
APPENDIX: GLOSSARY OF TERMS	126
GLOSSARY OF TERMS	126
GLOSSARY OF TERMS (CONTINUED).....	127
GLOSSARY OF TERMS (CONTINUED).....	128